Publication: 3176

Quality‐adjusted survival with first‐line cabozantinib or sunitinib for advanced renal cell carcinoma in the CABOSUN randomized clinical trial (Alliance)
      QxMD      Google Scholar   
Citation:
Cancer vol 126 (24) 5311-5318
Year:
2020
Type:
Manuscript
Funding:
NCTN
Endpoint:
Secondary-not-in-original
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
Received
Note:
Methodological:
No
Biospecimen:
No
SDC:
No
Book Volume:
10
Parents:
2908  
Children:
None
Program:
OGC
Primary Committee:
GU
Sec. Committees:
   
Pharmas:
Ipsen and Exelixis  
Grants:
U10CA180821, U10CA180882, UG1CA189823  
Corr. Author:
 
Authors:
                     
Networks:
FL023, KANSAS, LAPS-MA036, LAPS-NC010, LAPS-NY016   
Study
Alliance-A031203
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
2
Keywords:
carcinoma, protein tyrosine kinases, quality of life, renal cell